Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Acute renal failure is caused by damage to the kidneys, which can occur as a result of blood loss, toxins, or physical damage to the kidneys. Acute renal failure occurs rapidly, causing generalized ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

Acute kidney injury was defined according ... Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1–180 days).

Chronic kidney disease is a common complication ... hypersensitivity, acute gallbladder disease, and pulmonary aspiration during anesthesia.

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

According to the NHS, a hacking cough is the primary symptom of the illness. One clear distinction is that a ...

New research connects mild acute kidney injury (AKI) with increased risks of dementia and cognitive impairment in older adults. Explore the implications for long-term cognitive health and care ...

Acute kidney injury (AKI) may progress to chronic kidney disease, and there is an urgent need for approaches that improve the limited regeneration of the renal tubules after AKI.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).